ECSP972115A - SUBSTITUTED OXYBUTYRIC ACIDS AS MATRIX METALOPROTEASE INHIBITORS - Google Patents

SUBSTITUTED OXYBUTYRIC ACIDS AS MATRIX METALOPROTEASE INHIBITORS

Info

Publication number
ECSP972115A
ECSP972115A ECSP972115A ECSP972115A EC SP972115 A ECSP972115 A EC SP972115A EC SP972115 A ECSP972115 A EC SP972115A EC SP972115 A ECSP972115 A EC SP972115A
Authority
EC
Ecuador
Prior art keywords
disorders
present
graph
carbons
alkyl
Prior art date
Application number
Other languages
Spanish (es)
Inventor
David R Brittelli
Jinshan Chen
Brian Richard Dixon
Zandt Michael C Van
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to ECSP972115 priority Critical patent/ECSP972115A/en
Publication of ECSP972115A publication Critical patent/ECSP972115A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención presenta composiciones farmacéuticas y métodos para tratar ciertos trastornos, que comprenden administrar una cantidad de un compuesto o composición de la presente invención que sea eficaz para inhibir la actividad de por lo menos una metaloproteasa de matriz, que da como resultado la obtención del efecto deseado. Los compuestos de la presente invención tiene la fórmula generalizada (gráfico), donde y es 0,2 ó 3, r es 0-6, Z es (CH2)7-O(CH2)e-C6H4-(CH2)r o donde e es 0-1 y f es 1-6; R15 es -H, -CI-=Me o (gráfico), donde n es 0-4, R17 es -C2H5,-arilo o -bencilo y R16 es (gráfico), donde t es 0-1, x es 0-4 y R4 es uno de los siguientes; haluro, alquilo de 1 a 6 carbonos, OR, NR2, NO2, (R=H o alquilo de 1 a 6 carbonos). Estos compuestos son útiles para inhibir las metaloproteasas de matriz y, por lo tanto, para combatir los trastornos a los cuales contribuyen las MMP, tales como la osteoartritis, la artritis reumatoidea, la artritis séptica, las enfermedades periodontales, las úlceras de córnea, la proteinuria, la enfermedad de aneurisma aórtico, la epidermolisis vesicular distrófica, los trastornos que producen respuestas inflamatorias, las osterpenias en las que media la actividad de MMP, la enfermedad de la articulación temporomandibular, las enfermedades desmielinizantes del sistema nervioso, las metástasis de tumores o la pérdida degenerativa de cartilago posterior a la lesión articular traumática, y la trombosis coronaria a partir de la ruptura de placa ateroesclerótica. La presente invención se relaciona asi mismo con composiciones farmacéuticas y métodos para tratar dichos trastornos.The present invention features pharmaceutical compositions and methods of treating certain disorders, which comprise administering an amount of a compound or composition of the present invention that is effective in inhibiting the activity of at least one matrix metalloprotease, resulting in obtaining the desired effect. The compounds of the present invention have the generalized formula (graph), where y is 0.2 or 3, r is 0-6, Z is (CH2) 7-O (CH2) e-C6H4- (CH2) ro where e is 0-1 and f is 1-6; R15 is -H, -CI- = Me or (graph), where n is 0-4, R17 is -C2H5, -aryl or -benzyl, and R16 is (graph), where t is 0-1, x is 0- 4 and R4 is one of the following; halide, alkyl of 1 to 6 carbons, OR, NR2, NO2, (R = H or alkyl of 1 to 6 carbons). These compounds are useful for inhibiting matrix metalloproteases and, therefore, for combating disorders to which MMPs contribute, such as osteoarthritis, rheumatoid arthritis, septic arthritis, periodontal diseases, corneal ulcers, proteinuria, aortic aneurysm disease, dystrophic vesicular epidermolysis, disorders that produce inflammatory responses, osterpenias in which MMP activity mediates, temporomandibular joint disease, demyelinating diseases of the nervous system, tumor metastasis, or degenerative loss of cartilage after traumatic joint injury, and coronary thrombosis from atherosclerotic plaque rupture. The present invention likewise relates to pharmaceutical compositions and methods of treating such disorders.

ECSP972115 1997-05-12 1997-05-12 SUBSTITUTED OXYBUTYRIC ACIDS AS MATRIX METALOPROTEASE INHIBITORS ECSP972115A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ECSP972115 ECSP972115A (en) 1997-05-12 1997-05-12 SUBSTITUTED OXYBUTYRIC ACIDS AS MATRIX METALOPROTEASE INHIBITORS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ECSP972115 ECSP972115A (en) 1997-05-12 1997-05-12 SUBSTITUTED OXYBUTYRIC ACIDS AS MATRIX METALOPROTEASE INHIBITORS

Publications (1)

Publication Number Publication Date
ECSP972115A true ECSP972115A (en) 1998-04-24

Family

ID=42042946

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP972115 ECSP972115A (en) 1997-05-12 1997-05-12 SUBSTITUTED OXYBUTYRIC ACIDS AS MATRIX METALOPROTEASE INHIBITORS

Country Status (1)

Country Link
EC (1) ECSP972115A (en)

Similar Documents

Publication Publication Date Title
ATE89263T1 (en) NAPHTHALINE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
ES2036190T3 (en) NEW DERIVATIVES OF DIPHOSPHONIC ACIDS, PROCEDURE FOR THE PREPARATION AND MEDICINES CONTAINED IN THESE COMPOUNDS.
ES2056810T3 (en) DERIVATIVES OF PHOSPHINIC ACID.
HN1997000067A (en) SUBSTITUTED OXYBUTYRIC ACIDS AS MATRIX METALOPROTEASE INHIBITORS
ES2014220B3 (en) NEW DERIVATIVES OF DIPHOSPHONIC ACID, PROCEDURE FOR ITS PREPARATION AND MEDICINES CONTAINED IN THESE COMPOUNDS.
AR007098A1 (en) MATRIX METALOPROTEASE INHIBITORS, COMPOSITIONS UNDERSTANDING THEM, AND USE OF THEM TO PREPARE PHARMACEUTICAL COMPOSITIONS
ATE203409T1 (en) PHOSPHONOCARBOXYLATE COMPOUNDS FOR TREATING ABNORMAL CALCIUM AND PHOSPHATE METABOLISM
ES2078507T3 (en) MEDICINES AND DERIVATIVES OF SULFONANILIDE.
AR007096A1 (en) MATRIX METALOPROTEASE INHIBITOR COMPOUND METHOD FOR INHIBITING ITS ACTIVITY, A CONTAINING COMPOSITION AND USE OF SUCH COMPOUNDS TO PREPARE PHARMACEUTICAL COMPOSITIONS
AR007100A1 (en) INHIBITION OF MATRIX METALOPROTEASES BY SUBSTITUTED PHENYLALKYL COMPOUNDS AND THE USE OF THE SAME FOR THE PREPARATION OF A MEDICINAL PRODUCT.
BR0008778A (en) Prostaglandin analogs selective for unsaturated fpc16
AR007097A1 (en) BIARYLACETHYLENE MATRIX METALOPROTEASE INHIBITORS, A COMPOSITION THAT HAS MATRIX METALOPROTEASE INHIBITING AND THE USE OF SUCH BIARYLACETILENE IN THE MANUFACTURE OF A MEDICINAL PRODUCT.
ECSP972115A (en) SUBSTITUTED OXYBUTYRIC ACIDS AS MATRIX METALOPROTEASE INHIBITORS
DE69600272D1 (en) Quinoline-4-carbonylguanidine derivatives, processes for their preparation and pharmaceutical compositions containing them
ECSP972111A (en) MATRIX METALOPROTEINASES INHIBITORS BY ACIDS 2- (AROILALQUIL) -4 BIARIL-4- OXOBUTIRICOS
ECSP972112A (en) INHIBITION OF MATRIX METALOPROTEASES BY SUBSTITUTED FENETILE COMPOUNDS
ECSP972113A (en) INHIBITION OF MATRIX METALOPROTEASES BY SUBSTITUTED BIARILOXOBUTIRIC ACIDS
PA8429601A1 (en) INHIBITION OF MATRIX METALOPROTEINASES BY ACIDS 2- (W-AROILALQUIL) -4-BIARIL-4-OXOBUTIRICOS.
ECSP972114A (en) BIARYLACETYLENE AS INHIBITORS OF MATRIX METALOPROTEASE
AU665968B2 (en) New non ionic iodized agents for X-ray contrasting, method for preparing them and galenical compositions containing them
TH12333B (en) Inhibition of matrix methalloprotein by substitutedphenethyl compounds.
TH35864A (en) Inhibition of matrix methalloprotein by substitutedphenethyl compounds.
RU2201226C1 (en) Antiepileptic agent with nootropic effect
ATE160771T1 (en) NEW ALKENECARBOXYLIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
TH9798EX (en) 2-amino-4-morfolino-6-1,3,5-triazine